Skip to content Skip to menu

Medicines Australia welcomes new MTPConnect CEO

Monday, 7 May 2018

Media Release

Medicines Australia (MA) congratulates MTPConnect on the appointment of Dr Dan Grant as Chief Executive Officer.  Dr Grant has extensive background and experience in the pharmaceutical sector and academia – most recently as Pro Vice Chancellor at La Trobe University and as head of External Research and Development Innovation Group at Pfizer.

Interim CEO of MA, Ms Elizabeth de Somer said, “Medicines Australia and MTPConnect share the same goals of increasing industry collaboration, investment and innovation.”

“Dr Grant’s extensive experience in pharmaceutical innovation make him the ideal person to further the agenda of the important MTP sector,”

“Medicines Australia and our members look forward to working with Dr Grant to continue our already close collaboration with MTPConnect,” said Ms de Somer.

MA also recognises the outstanding contribution of Sue MacLeman who, as announced in February, will assume the position of Chair.

“Under Sue’s direction, MTPConnect and Medicines Australia signed an MOU to ensure continued collaboration,”

“In addition to that, MA and consortia of our members are partnering with MTPConnect on three projects: The Bridge Program – which along with QUT, helps participants understand and navigate the complex regulatory, financial, scientific and intellectual property issues involved in translating promising research into new medicines for market; The tele-trials program – working with the Clinical Oncology Society of Australia to broaden the reach of clinical trials into remote and regional areas; and the Value of Medicines project, which will review and quantify the value of medicines and the medicines industry to the community,” said Ms de Somer.

“Ms MacLeman has been a tireless advocate for the MTP sector and wish her well in her future role as Chair of MTPConnect,” said Ms de Somer.



As COVID19 continues to spread, our thoughts go out to anyone who has been infected or impacted. We hope that you are taking the necessary precautions to keep safe and well, both at work and at home.

Medicines Australia continues to monitor the situation and take advice from the Department of Health and the World Health Organisation. We are focused on responding to the important short-term issues but are also ensuring we stay balanced and maintain a focus on the medium and long-term business for our industry along with the well-being of our people.

At Medicines Australia we have initiated the following to ensure we support containment measures to provide business continuity and the well-being of our staff.

  • All non-essential travel has been restricted or cancelled
  • All face-to-face meetings (with external stakeholders and members) have been changed to virtual meetings (where appropriate)
  • Staff have been provided with the latest official information on COVID-19 through a hot-link on the office intranet; this information is regularly monitored and updated
  • Flexible working arrangements are covered in our HR policy which will allow staff to work remotely, if or when required
  • Current IT infrastructure enables staff to work remotely and will be in use if any person needs to self-isolate
  • Visual reminders have been displayed around the office, providing information about best hygiene practices
  • Extra hand-sanitiser, tissues and cleaning products have been supplied to staff for their work spaces

Our latest information is located at